SCHEMBL230032

SCHEMBL230032

COC(=O)c1cc(N)cc(C(=O)c2ccc(N(C)c3ccc(Cl)cc3)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
ALDH1A1 P00352 6/20 0.44
HPGD P15428 4/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
LTC4S Q16873 1/20 0.41
ABL1 P00519 1/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.39
CNR1 P21554 1/20 0.39
ELANE P08246 1/20 0.39
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL232400 0.91 HPGD (0.46) MAPTALDH1A1HPGDLMNAKDM4E
SCHEMBL229900 0.87 TUBB4A (0.45) MAPTALDH1A1HPGDLMNAKDM4E
SCHEMBL232232 0.86 LMNA (0.50) MAPTALDH1A1HPGDLMNAL3MBTL1
SCHEMBL230254 0.84 MAPT (0.49) MAPTALDH1A1HPGDLMNAKDM4E
SCHEMBL233571 0.83 MEN1 (0.55) MAPTALDH1A1HPGDSMN1; SMN2LTC4S
SCHEMBL231253 0.82 LMNA (0.46) MAPTALDH1A1HPGDLMNAL3MBTL1
SCHEMBL232108 0.82 MAPT (0.44) MAPTALDH1A1HPGDLMNAKDM4E
SCHEMBL231986 0.81 RAB9A (0.47) MAPTALDH1A1LMNAKDM4EL3MBTL1
SCHEMBL232161 0.79 HPGD (0.42) MAPTHPGDLMNAL3MBTL1SMN1; SMN2
SCHEMBL232464 0.79 LTC4S (0.48) MAPTALDH1A1HPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406220-A1 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS Biolipox AB (SE) 2012-01-18 EP disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
WO-2010103279-A1 BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS BIOLIPOX AB (SE) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R MAPT 4117/4885ALDH1A1 453/4885HPGD 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.